

Fine Foods Group has signed a binding agreement to acquire all the shares of Sofar S.p.A., a company owned by the Alfasigma Group

With this acquisition, Fine Foods & Pharmaceuticals N.T.M. S.p.A. will broaden its portfolio to include new dosage forms further enhancing its competitive standing.

Verdellino (Bergamo, Italy), April, 17 2026 - **Fine Foods & Pharmaceuticals N.T.M. S.p.A.** - an Italian independent Contract Solutions Development & Manufacturing Organization (CSDMO) specialising in the contract development and manufacturing of products for the nutraceutical, pharmaceutical, and cosmetics industries, listed on Euronext STAR Milan (ticker: FF) signed today a binding agreement with **Alfasigma S.p.A.**, a global pharmaceutical company headquartered in Italy with more than 75 years of experience, to acquire all of the share capital of **Sofar S.p.A.**, an Alfasigma subsidiary with a manufacturing facility in Trezzano Rosa (Milan).

The transaction aligns with Fine Foods' industrial strategy to strengthen and broaden its production capabilities. The acquisition allows Fine Foods to add expertise and technology for producing liquid and semi-solid pharmaceuticals, expanding its industrial capabilities.

By completing this transaction, the company broadens its service portfolio, reinforces Fine Foods' competitive role as a strategic and integrated partner, and enhances its capability to secure new projects and customers.

The acquisition of all Sofar shares pursues operational and organisational continuity, while enhancing the industrial partnership with Alfasigma, which will retain ownership of products currently manufactured at Trezzano Rosa. Alfasigma and Fine Foods will keep manufacturing and supplying products under a long-term contract.

Fine Foods & Pharmaceuticals N.T.M. S.P.A. Managing Director Pietro Oriani said: *"This acquisition is a strategic move for Fine Foods, which adds valuable technology. By integrating specialised technology for liquid and semi-solid production, we provide comprehensive support to customers across the development and manufacturing process, while expanding our services and solutions to strengthen our role as a strategic partner. This transaction strengthens Fine Foods' competitive position and deepens its partnership with a leading industrial group, supporting the company's focus on selective growth and lasting relationships".*

Alfasigma S.p.A. Chief Executive Officer Francesco Balestrieri said: *"We are pleased to partner with Fine Foods, a well-qualified manufacturer, on this long-term agreement and look forward to a reliable and productive working relationship. As Alfasigma continues to grow at pace, we are making deliberate strategic choices to remain focused on what matters most. By streamlining elements of our manufacturing footprint, we are strengthening our capacity to invest selectively in areas where we can be distinctive and make the greatest impact. This focus allows us to accelerate innovation and support our core therapeutic priorities in immunology, gastroenterology and vascular disease. Italy remains a cornerstone of Alfasigma's industrial and strategic presence".*

The transaction values Sofar S.p.A. at an enterprise value of €27 million.

In 2025, Sofar S.p.A. reported:

- Net revenue of €31.8 million
- EBITDA of €8.9 million
- Net profit of €4.4 million.

The transaction is anticipated to be completed by the first half of June 2026, subject to meeting standard conditions for this type of deal, such as the non-exercise of special powers under the Golden Power legislation.

Funding will come from company resources and bank loans.

For this transaction, Fine Foods received financial advice from KPMG and legal counsel from GA-Alliance. Alfasigma, meanwhile, was supported by EY Parthenon which acted as its financial advisor.

You can find the definition of alternative performance indicators in the "Alternative Performance Indicators" section of the Annual Financial Report.

The Company shares regulated information through the authorised 1info storage system managed by Computershare S.p.A. at www.1info.it.

This press release is available on the website www.finefoods.it, in the Investor Relations/Press Releases section.

Fine Foods & Pharmaceuticals N.T.M. S.p.A., listed on Borsa Italiana's Euronext STAR Milan (Ticker: FF) is an Italian independent Contract Solutions Development & Manufacturing Organization (CSDMO) specialising in the contract development and manufacturing of products for the nutraceutical, pharmaceutical and cosmetics industries, with a customer-centric, service-oriented philosophy. Founded in 1984, Fine Foods proved to be a reliable and capable strategic partner for customers in the reference sectors. The company's organisation can provide successful design process and solid, long-term partnerships. The continuous search for excellence is part of the company's business model and includes research and development, innovation, process reliability, product quality, ESG, and sustainable management of the Group's supply chain. Fine Foods is a benefit corporation which relies on certifications and ratings under international standards. These guarantee its sustainability commitment across the business. Fine Foods is a growing and future-oriented company.

Alfasigma is a global pharmaceutical company founded over 75 years ago in Italy, where it is headquartered today in Bologna and Milan. The Group's products are distributed in more than 100 markets worldwide. Alfasigma operates offices across major European countries, as well as in the United States, China, and Mexico; production facilities in Italy, Spain, and the United States; and R&D laboratories located in Italy. The company employs approximately 4,000 professionals dedicated to the research, development, production, and distribution of medicinal products. Its portfolio ranges from consumer healthcare products and primary care treatments to specialty and rare disease medications, with key therapeutic areas including gastroenterology, vascular health, and immunology.

For further information:

Fine Foods & Pharmaceuticals N.T.M. S.p.A.

Tel +39 035 4821382

Investor Relations: ir@finefoods.it

Media Relations: media.relations@finefoods.it